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The effects of Stachytarpheta jamaicensis tea on the plasma lipid profile and atherogenic 
indices were investigated in rabbits. The test group received daily, by intra-gastric gavages, 
15mg/kg of aqueous extract. The treatment led to significant decreases (p<0.05) in plasma 
levels of total, LDL- and VLDL-cholesterol and triglycerides, and increase (p<0.05) in 
plasma HDL cholesterol level. It also produced significant (p<0.05) decreases in the 
atherogenic indices; cardiac risk ratio, atherogenic coefficient and atherogenic index of 
plasma. These results suggest the use of Stachytarpheta jamaicensis tea in the management of 
dyslipidemia whether primary or secondary to obesity, diabetes mellitus and hypertension, 
and by extension, the reduction of the risk of cardiovascular diseases 
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Cardiovascular disease is one of the world’s 
leading causes of death. One of the major risk 
factors for the development of cardiovascular 
disease is dyslipidemia, which may be primary 






involve elevated plasma levels of triglycerides, 
total, LDL and VLDL cholesterol and a low 





nutritional and pharmacologic intervention that 
improves or normalizes abnormal lipid 
metabolism may be useful for reducing the 





are at present, available for the management of 
dyslipidemia. However, there is renewed 
interest in the use of herbal products
10,11
. This 
may be attributable to the down turn in the 
economy, as traditional medicine is perceived 





wonder, WHO in 1991, developed guidelines 
for the assessment of herbal medicine
10
. In 
Nigeria, a great number of plants are currently 
used in the management of a wide range of 
illnesses by traditional medical practitioners. 
Stachytarpheta jamaicensis is one of such 
plants. 
 
It is used in traditional medicine as an 
analgesic, antacid, anti-inflammatory, 
antispasmodic, antiulcerogenic, digestion 
stimulant, diuretic, febrifuge, gastroprotective, 






constituents include flavonoids, triterpenes, 
monoterpenes, iridoids, phytosterols, aromatic 
acids, GABA, dopamine and alkanes
15,17
. In 
spite of this multitude of ethnomedical 
applications, we found nothing in biochemical 
literature, relating to the effect of the plant on 
plasma lipid profiles. In view of this, we 
undertook a preliminary investigation in which 
we found that the aqueous infusion (tea) of 
Stachytarpheta jamaicensis significantly 
reduced the weight and plasma total 




Therefore, as a 
follow up, the present study was designed to 
investigate the effect of the tea on plasma lipid 
profile and some atherogenic indices of 
rabbits, with a view to finding any therapeutic 
benefit in the management of dyslipidemia – a 
risk factor for development of cardiovascular 
disease and a common characteristic of 
diabetes mellitus and hypertension – especially 
in view of the reports that the treatment of 





MATERIALS AND METHODS 
 
Preparation of the Leaves 
The tea bags were collected from the 
Integrated Services Unit of Benson Idahosa 
University, Benin City, Nigeria. See Idu et al 
20
 for a description of how to prepare the leaf 
powder. The tea bags were used to prepare 
aqueous infusions by placing a tea bag 
containing 1.8g of dried powdered plant 
(Stachytarpheta jamaicensis) in 250ml of 
boiled water for 8h to simulate the traditional 
procedure for preparing the tea. The resultant 
aqueous extract was stored for subsequent use. 
A known volume of this extract was 
evaporated to dryness, and the weight of the 
residue used to determine the concentration of 
the filtrate, which was in turn used to 
determine the dose of administration of the 
extract to the test animals. The dosage of 
dispensation/administration of the tea adopted 
in this study was extrapolated from that 
recommended on the tea packs (as 




Three-month old New Zealand white rabbits 
weighing between 0.85-1.5kg was obtained 
from a breeder in Benin City. The animals 
were housed in clean, disinfected hutches and 
acclimatized on guinea growers mash (Bendel 
Feed and Flour Mills Ltd., Ewu, Nigeria) for a 
week after which fasting blood samples were 
collected for the assay of baseline plasma lipid 
profiles. They were subsequently weighed and 
randomly assigned into two groups. The test 
group received by intra-gastric gavages, 15mg 
of aqueous extract/kg of body weight, while 
the control group received appropriate 
volumes of water by the same route. Fresh 
feed was provided daily, while stale remnants 
were discarded.  
 
The animals had free access to mash and 
water. The rabbits were weighed weekly to 
allow for adjustment in administration of the 
extract. The treatment lasted for 8 days. The 
fasting blood samples were collected on day 0 
73 
 
(baseline), 1 and 8, for determination of 
plasma lipid profiles. 
 
Determination of the Plasma Lipid 
Profiles/Indices 
Plasma total cholesterol (TC), HDL-
cholesterol (HDLC) and triglyceride (TG) 
were assayed enzymatically with commercial 
test kits (Randox Laboratories, Crumlin, 
England), at the Chemical Pathology 
Department, University of Benin Teaching 
Hospital (UBTH), Benin City, Nigeria. Plasma 
LDL-cholesterol was calculated using the 
Friedewald equation
21
, as follows: 
 
LDLC = TC – HDLC – TG/2.2. 
VLDLC = TG/2.2. 
The atherogenic indices were calculated as 
follows: 
 
Cardiac Risk Ratio (CRR) = TC/HDLC  
Atherogenic Coefficient (AC) = (TC– HDLC)/HDLC 
 
 
Atherogenic Index of Plasma(AIP)= log(TG/HDLC) 
 
Statistical Analysis of Data 
All values are quoted as the mean ± S.E.M. 
The values of the various parameters for the 
test and control groups were analyzed for 
statistical significant differences using the 






The treatment led to significantly lower 
(p<0.05) plasma levels of total, LDL- and 
VLDL-cholesterol, and triglycerides. These 
parameters were significantly lower in the test 
group compared to the control and baseline 
values (Table 1).  
 
Table 1: Time course of the effects of Stachytarpheta jamaicensis tea on plasma lipid profiles of 
normal rabbits. 
Time  Concentration (mmol/L) 
Control Test  
a) Plasma total cholesterol 
Baseline 2.389±0.149 
Day 1                            2.461±0.026              2.176±0.052*                                      
Day 8                            2.163±0.039                     1.981±0.013*
+
 
b) Plasma LDL cholesterol 
Baseline 1.464±0.132 
Day 1                            1.553±0.026 1.334±0.010* 
Day 8                            1.360±0.071 1.144±0.090*
+
 
c) Plasma VLDL cholesterol 
Baseline 0.394±0.007 
Day 1                            0.480±0.013 0.311±0.003*
+
 
Day 8                            0.362±0.059 0.254±0.039
+
 
d) Plasma triglyceride 
Baseline 0.867±0.016 
Day 1                            1.057±0.028 0.684±0.006*
+
 
Day 8                            0.797±0.130 0.559±0.085 
+
 
e) HDL cholesterol 
Baseline 0.530±0.017 
Day 1                            0.427±0.013 0.531±0.065 
Day 8                            0.440±0.026 0.583±0.039*  
Concentrations are expressed as mean ± SEM. *p<0.05 compared to control, +p<0.05 compared to baseline, 





The treatment produced a gradual rise (p<0.10 
on day 1 to p<0.005 on day 8) in plasma HDL-
cholesterol levels; although these values were 
only significant at p<0.10 when compared to 
the baseline HDL-cholesterol levels. The 
treatment also significantly lowered (p<0.05) 
the following atherogenic indices; cardiac risk 
ratio (CRR), atherogenic coefficient (AC) and 
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atherogenic index of plasma (AIP) (Table 2).  
 
Table 2: Time course of the effects of 
Stachytarpheta jamaicensis tea on the 
atherogenic indices of normal rabbits. 
Time  Atherogenic index 
Control Test  
a) Cardiac risk ratio                                           
Baseline 4.494±0.209 
Day 1                            5.765±0.235 4.147±0.408*                                      
Day 8                            4.924±0.201 3.417±0.250*
+
 
b) Atherogenic coefficient 
Baseline 3.494±0.209 
Day 1                            4.765±0.235 3.147±0.408* 
Day 8                            3.924±0.201 2.417±0.250*
+
 
c) Atherogenic index of Plasma 
Baseline 0.214±0.009 
Day 1                            0.393±0.025 0.113±0.057* 
Day 8                            0.253±0.097 -0.022±0.037*+ 
Indices are expressed as mean ± SEM. *p<0.05 
compared to control, +p<0.05 compared to baseline, n=4 
per group.  
 
After treatment, the values of each of these 
parameters in the test group, were significantly 





Epidemiological studies have shown that an 
elevated concentration of total cholesterol in 
the blood is a powerful risk factor for coronary 
disease
26,27
. In this study, the tea significantly 
lowered plasma total cholesterol of the rabbits 





Presently, though the constituent(s) of 
this decoction that possesses the 
hypocholesterolemic effect is yet to be 
specifically identified, there is evidence that 
the plant contains monoterpenoids, 
isoflavones, esters of triterpene alcohols and 
phytosterols. Since monoterpenoids, 
isoflavones, esters of triterpene alcohols and 
phytosterols
8,28-32
 from other plants sources, 
have all been independently reported to exert 
hypocholesterolemic effects, any one or a 
combination of these phytochemicals may be 
responsible for the effect observed in this 
study. 
 
Increased plasma levels of LDL and VLDL 




 and is a risk factor 
for cardiovascular disease
11,26,27,34,35
. In this 
study, we observed a significantly lower 
plasma LDL and VLDL cholesterol levels in 
the treated animals (Table 1b,c). This effect 
may be attributable to the flavonoid content of 
the plant. Middleton et al.
36
 had earlier 
reported that citrus flavonoids lower plasma 
LDL cholesterol in both normolipidemic and 
hyperlipidemic rats. Plant sterols are also 
known to lower plasma LDL cholesterol
30
. 
Decreases in plasma LDL cholesterol have 





A high plasma triglyceride level is both an 
independent and synergistic risk factor for 
cardiovascular diseases
8,25,37




lipoprotein metabolism, obesity, insulin 
resistance and diabetes mellitus
3,9,37
. The tea 
significantly reduced plasma levels of 
triglycerides (Table 1d). This effect may have 
been mediated by the flavonoid content of the 





Low plasma HDL cholesterol is a risk factor 
for cardiovascular diseases
7,8,34,35,38
 and is often 
found in hypertension
2,33
 and diabetes 
mellitus
1,3,7,9
. In this study, the tea increased 
plasma HDL cholesterol levels (Table 1e), an 
effect that may again be mediated by the 
flavonoids; since according to Middleton et 
al.
36
 flavonoids increased plasma HDL 
cholesterol in both normolipidemic and 
hyperlipidemic rats. Increases in plasma HDL 
cholesterol have been considered to reduce 
risk in coronary heart disease
7,38
. High HDL 
exerts a protective effect by enhancing reverse 
cholesterol transport by scavenging excess 
cholesterol from peripheral tissues, which it 
esterifies with the aid of lecithin: cholesterol 
acyltransferase, and  delivers to the liver and 
steroidogenic organs for subsequent synthesis 
of bile acids and lipoproteins, and eventual 
elimination from the body
27,38,39
; and inhibiting 
the oxidation of LDL as well as the 








Atherogenic indices are powerful indicators of 
the risk of heart disease: the higher the value, 
the higher the risk of developing 
cardiovascular disease and vice versa
8,22-25,42
. 
In this study, we observed that the tea 
significantly reduced atherogenic indices CRR 
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(Table 2a), AC (Table 2b) and AIP (Table 2c). 
According to Usoro et al.
42
 lower atherogenic 
index is protective against coronary heart 
disease. 
 
All of these results indicate a possible 
protective mechanism of the tea against the 
development of atherosclerosis and coronary 
heart disease, as well as the dyslipidemic 
conditions that characterize hypertension and 
diabetes mellitus. Provided animal to human 
extrapolation is allowed, the therapeutic 
implication of this result to the management of 
hypertension cannot be overemphasized, 
especially in view of the reports that some 
commonly used antihypertensive diuretic 
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